| Literature DB >> 31419969 |
Bin Ding1, Qinchao Ding1, Shun Zhang2, Zhuo Jin1, Zhaolei Wang1, Songtao Li1, Xiaobing Dou3.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) causes serious infections in hospitals. Penthorum chinense Pursh (PCP), employed by the Miao ethnic minority in China, presents antibacterial activities. In this study, the anti-Staphylococcus aureus activities in the pinocembrin-7-O residue-rich fraction from PCP (PGF) were evaluated and characterized.Entities:
Keywords: Bactericidal activity; Bacteriostatic activity; Penthorum chinense pursh; Staphylococcus aureus (S. aureus)
Mesh:
Substances:
Year: 2019 PMID: 31419969 PMCID: PMC6697954 DOI: 10.1186/s12906-019-2632-3
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1HPLC analysis of the PGF from PCP. First, 10 μL of the PGF (10 mg/mL) was analysed with a C18 reversed-phase column (Dionex). The process was monitored by a 254 nm UV detector. The Rt values of S1, S2 and S3 were 17.94, 20.22 and 22.13 min, respectively
IZDs (mm) of different fractions of PCP extracts
| Standard Strains | Fractions (10 mg/mL) | PGF (5 mg /mL) | Van (10 μg /mL) | |||
|---|---|---|---|---|---|---|
| PF | EAF | BuOHF | WF | |||
|
| 8.33 ± 0.58 | 6.83 ± 0.29 |
| 7.80 ± 0.30 | 23.85 ± 0.43 | |
|
| 10.75 ± 0.35 | 6.50 ± 0.71 |
| 8.38 ± 0.60 | 26.23 ± 0.31 | |
|
| 9.67 ± 0.82 | 6.67 ± 0.52 |
| 8.00 ± 0.26 | 27.35 ± 0.25 | |
|
| 9.33 ± 0.58 | 6.67 ± 0.58 |
| 7.86 ± 0.69 | Nd | |
|
| 10.83 ± 0.98 | 6.33 ± 0.52 |
| 8.80 ± 1.30 | Nd | |
|
| 10.50 ± 0.71 | 6.50 ± 0.71 |
| 7.33 ± 0.52 | Nd | |
|
| 12.67 ± 0.58 | 6.33 ± 0.58 |
| 12.00 ± 0.83 | Nd | |
Note: In the experiment, DMSO- and water-impregnated paper discs were used as negative controls. “-” indicates that no visible inhibition zone was observed. “Nd” means not detected
IZDs (mm) of the PGF against different MRSA strains
| Clinical Strains | Resistant (R) | Susceptible (S) | Intermediate (I) | IZDs |
|---|---|---|---|---|
| MRSA 170925062 | CLI, CIP, CN, LEV, OX, PEN, SXT, TE, E, MXF | F, VAN, LZD, QD, TGC | RD | 9.0 ± 0.35 |
| MRSA 925059 | OX, PEN | CLI, CIP, CN, TE, F, LEV, RD, SXT, VAN, E, MXF, LZD, QD, TGC | – | 9.1 ± 0.43 |
| MRSA 920057–1 | CLI, CIP, CN, LEV, OX, PEN, SXT, TE, E, MXF | F, VAN, LZD, QD, TGC | RD | 9.0 ± 0.74 |
| MRSA 912036–2 | CLI, CIP, CN, LEV, OX, PEN, SXT, TE, E, MXF | F, VAN, LZD, QD, TGC | RD | 8.1 ± 0.43 |
| MRSA 912037 | CLI, CIP, CN, LEV, OX, PEN, SXT, TE, E, MXF | F, VAN, LZD, QD, TGC | RD | 11.2 ± 0.76 |
| MRSA 1223064–1 | CLI, CIP, LEV, OX, PEN, SXT, TE, E, MXF | F, CN, VAN, LZD, QD, TGC | RD | 10.4 ± 0.43 |
| MRSA 1224057–1 | CLI, CIP, LEV, OX, PEN, E, MXF | F, CN, VAN, LZD, QD, TGC, TE, RD, SXT | – | 10.1 ± 0.75 |
Note: “-” indicates that no visible inhibition zone was observed
Abbreviations: CIP Ciprofloxacin, CLI Clindamycin, CN Cephalexin, E Erythromycin, F Nitrofurantoin, LEV Levofloxacin, LZD Linezolid, MXF Moxifloxacin, OX Oxacillin, PEN Penicillin, QD Quinupristin/dalfopristin, RD Rifampicin, SXT Sulfamethoxazole/trimethoprim, 19:1, TE Tetracycline, TGC Tigecycline, VAN Vancomycin
MICs and MBCs of the PGF, S1, S2, and S3
| MICs, MBCs and MIC/MBC ratios of the active fraction, components and vancomycin (μg/mL) | Test strains | |
|---|---|---|
| PGF | ||
| MIC | 62.5 | 62.5 |
| MBC | 125 | 250 |
| MBC/MIC | 2 | 4 |
| S1 | ||
| MIC | 62.5 | 62.5 |
| MBC | – | – |
| MBC/MIC | – | – |
| S2 | ||
| MIC | 62.5 | 62.5 |
| MBC | – | 500 |
| MBC/MIC | – | 8 |
| S3 | ||
| MIC | 62.5 | 62.5 |
| MBC | 250 | 250 |
| MBC/MIC | 4 | 4 |
| Vancomycin | ||
| MIC | 2 | 2 |
| MBC | 2 | 2 |
| MBC/MIC | 1 | 1 |
Note: “-” indicates the value could not be identified
Fig. 2Time-dependent killing activities of the PGF on strains ATCC 25923 and ATCC 43300. All the CFU values are the average of 6 repeats
Fig. 3Time-dependent killing activities of S3 on the strains ATCC 25923 and ATCC 43300. All the CFU values are the average of 6 repeats
Postantibiotic effects of the PGF
| Con. of the PGF | Mean of PAE ± st (h) | |
|---|---|---|
| 63 μg/mL | 1.47 ± 0.30 | 0.28 ± 0.17 |
| 125 μg/mL | 1.49 ± 0.36 | 1.13 ± 0.16 |
| 250 μg/mL | 1.94 ± 0.45 | 4.68 ± 0.87 |
Fig. 4Influence of the PGF and S3 on cell viability. The PGF decreased cell viability in a dose-dependent manner, as shown by the MTT assay. NCTC 1469 cells were incubated with increasing concentrations of the PGF or S3 for 18 h. * * P < 0.01 vs. UT (0 μg/mL). UT indicates an untreated control